Pages
Products
scAAV9-Cre

scAAV9-Cre

Cat.No. :  AAV00256Z

Titer: ≥1x10^12 GC/mL / ≥1x10^13 GC/mL Size: 30 ul/100 ul/500 ul/1 ml

Serotype:  AAV Serotype 9 Storage:  -80 ℃

Inquire for Price

AAV Particle Information

Quality Control

Cat. No. AAV00256Z
Description Self-complementary AAV serotype 9 particles contain Cre recombinase under the control of CMV promoter.
Serotype AAV Serotype 9
Titer Varies lot by lot, typically ≥1x10^12 GC/mL
Size Varies lot by lot, for example, 30 μL, 50 μL, 100 μL etc.
Storage Store at -80℃. Avoid multiple freeze/thaw cycles.
Shipping Frozen on dry ice
Creative Biogene ensures high-quality AAV particles by optimizing and standardizing production protocols and performing stringent quality control (QC). The specific QC experiments performed vary between AAV particle lots.
Endotoxin Endotoxins, primarily derived from Gram-negative bacteria, can trigger adverse immune responses. Endotoxin contamination is a significant concern in the production of AAV, especially for applications in animal studies and gene therapy. Effective endotoxin quality control is essential in the development and manufacturing of AAV particles. Creative Biogene utilizes rigorous endotoxin detection methods to monitor the endotoxin level in our produced AAV particles to ensure regulatory compliance.
Purity AAV purity is critical for ensuring the safety and efficacy of AAV-based applications.AAV capsids are composed of three main protein components, known as viral proteins: VP1, VP2, and VP3. These proteins play a critical role in the structure and functionality of the AAV capsid. Monitoring the VP1, VP2, and VP3 content in AAV preparations is essential for quality control in AAV production. Our AAV particles are tested for showing three clear bands of VP1, VP2 VP3 by SDS-PAGE.
Sterility The AAV virus samples are inoculated into the cell culture medium for about 5 days to detect bacterial and fungal growth.
Transducibility Upon requirement, Creative Biogene can perform in vitro or in vivo transduction assays to evaluate the ability of AAV to deliver genetic material into target cells or tissues, and assess gene expression and functional activities.
Empty vs. Full Capsids Based-on our proprietary AAV production and purification technology, Creative Biogene can always offer AAV particles with high ratio of full capsids. If required, we can also assess the ratio for a specifc lot of AAV particles by transmission electron microscopy (TEM) or other methods.
Quick Inquiry

Background

Case Study

Publications

Q & A

Customer Reviews

Gene transfer vectors based on adeno-associated virus (AAV) have shown great promise for human gene therapy. AAV has attractive gene transfer properties. Wild-type AAV consists of a single-stranded DNA genome encoding replication (rep) and encapsidation (cap) genes flanked by inverted terminal repeats (ITRs). Recombinant AAV vectors are typically produced by transient transfection using a "gutless" vector approach. The therapeutic gene of interest is inserted along with regulatory elements between the 5' and 3' viral inverted terminal repeats (ITRs) and encoded on one plasmid. The rep and cap functions are provided in trans on separate plasmids, and a third plasmid provides the required adenoviral helper genes E4, E2, and Va RNA. Due to the ability of AAV9 vectors to penetrate the blood-brain barrier, they can be used to transfer genes en bloc to the brain and spinal cord, which has led to the treatment of a variety of central nervous system diseases via intravascular gene delivery. Intravenous administration of scAAV9 vectors has been shown to be a feasible and translatable approach for targeting the CNS in mice, cats, and non-human primates, and the approach is being used in human trials for spinal muscular atrophy. These studies have demonstrated the ability of AAV9 to achieve broad CNS transduction, all of which rely on more efficient self-complementary AAV (scAAV) vector designs. In vivo testing has shown that scAAV vectors are more than 10-fold more efficient at transducing cells compared to conventional single-stranded AAV (ssAAV) vectors.

Birdsong, like human language, consists of a sequence of temporally precise movements acquired through vocal learning. The learning of such sequential vocalizations depends on the neural function of the motor cortex and basal ganglia. Here, researchers used the songbird zebra finch as an animal model to explore the function of connections between the cortex-like (HVC) and basal ganglia (area X), which are connected via HVC(X) projection neurons and have temporally precise firing during singing. By specifically ablating HVC(X) neurons, juvenile zebra finches failed to imitate the acoustics of the guide syllables and developed songs that were temporally unstable with poor sequence consistency. In contrast, HVC(X)-ablated adults did not alter their learned song structure, but generated acoustic fluctuations and responded to auditory feedback disruption by the introduction of song deterioration, as did normal adults. These results suggest that cortico-basal ganglia inputs are important for learning the acoustic and temporal aspects of song structure but not for generating vocal fluctuations that help maintain already learned vocal patterns.

The researchers first injected scAAV9-Cre and scAAV9-FLExmRuby2 into area X and HVC, respectively, to test the induction rate and expression time of the target gene (i.e., mRuby2) in HVC(X) neurons. One week after injection, selective expression of mRuby2 protein in HVC(X) neurons was observed (Figure 1C). Neurotensin (NTS) mRNA was used as a marker of HVC(X) neurons. The study confirmed that NTS mRNA was specifically expressed in HVC(X) neurons labeled by retrograde cholera toxin B (CTB) injected into area X, but not in HVC(RA) neurons (Figure 1D). Using NTS labeling, a reliable estimation of residual HVC(X) neuron number after ablation could be performed without additional retrograde labeling from area X to HVC. The researchers then injected scAAV9-Cre into area X of the test hemisphere and injected a mixture of scAAV9-FLEx-dtA and -caCasp into HVC. In the other hemisphere of the same animal, scAAV9-Cre and scAAV9-FLEx-mRuby2 were injected into area X and HVC, respectively, to serve as the control hemisphere. The number of HVC(X) neurons was compared between the control and HVC(X)-ablated hemispheres (Figure 1D). As a result, the residual number of HVC(X) neurons was reduced to 23.9 to 57.2% in the ablated hemisphere when compared to the control HVC of the same individual. Although the cell ablation procedure failed to completely remove HVC(X) neurons, the approach using the mixture of dtA and caCasp showed a similar or higher rate of effective reduction of target cells compared to previous efforts to perform cell ablation in songbirds.

Specific ablation of HVC(X) neurons projecting to the basal ganglia area X.Figure 1. Specific ablation of HVC(X) neurons projecting to the basal ganglia area X. (Sánchez-Valpuesta M, et al., 2019)

Ask a Question

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

Customer Reviews
Reliable Results

We’ve used scAAV9-Cre in multiple experiments, and it consistently delivers reliable results. The transduction efficiency is impressive, and we have achieved consistent gene recombination across different batches.

Canada

04/22/2024

Write a Review

Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.

Needs improvement

Satisfaction

General satisfaction

Very satisfaction